Clinical Trials

80 enrolled

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT06561425 2026-03-16

Atalanta-1

130 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05421663 2026-03-13

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

439 enrolled

Phase 1/2 Not yet recruiting

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07439653 2026-02-27

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

155 enrolled

Lymphoma, B-Cell

NCT05826535 2026-02-24

Study of LYL314 in Aggressive Large B-Cell Lymphoma

270 enrolled

Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Disease Attributes

NCT07123454 2026-02-24

Lumi-NHL

91 enrolled

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell

NCT03598608 2026-02-05

MK-4280-003

137 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT06564038 2026-02-05

Soundtrack-E

276 enrolled

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT07376642 2026-01-29

A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

30 enrolled

Lymphoma, B-Cell

NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

LymphoidOther hematologic neoplasmSarcoma

803 enrolled 2 FDA

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT05643742 2025-11-14

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

120 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04329728 2025-11-03

OPAL

144 enrolled

Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoproliferative Disorders, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, T-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04035434 2025-10-24

A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

93 enrolled 27 charts

Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT02625480 2025-09-29

ZUMA-4

95 enrolled

Recurrence, Lymphoma, B-Cell

NCT03162536 2025-09-08

ARQ 531-101

LymphoidOther hematologic neoplasmPlasma cellSarcoma

190 enrolled

Blood Protein Disorders, Cardiovascular Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Recurrence, Vascular Diseases, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Hemostatic Disorders, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating

NCT06343311 2025-08-07

STARLIGHT-1

21 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Primary Effusion

NCT06492304 2025-06-29

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies

290 enrolled

Leukemia, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell

NCT04104776 2025-05-15

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

GenitourinaryGynecologicLymphoidOther solid neoplasmThoracic

275 enrolled

Mesothelioma, Malignant, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT05463263 2025-04-15

A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

180 enrolled

Lymphoma, B-Cell, Lymphoma, T-Cell

NCT05296525 2025-03-25

Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL

13 enrolled 10 charts

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04148742 2025-02-25

Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)

Phase 1/2 Withdrawn

Lymphoma, B-Cell

NCT05201248 2025-01-07

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

49 enrolled

Neoplasms, Lymphoma, B-Cell

NCT03677141 2024-12-18

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

117 enrolled 26 charts

Lymphoma, B-Cell

NCT05588440 2024-12-05

A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

9 enrolled 11 charts

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03671018 2024-11-29

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

422 enrolled

Lymphoma, B-Cell

NCT03664635 2024-11-21

MB-CART20.1 Lymphoma

10 enrolled

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell

NCT05720052 2024-07-18

A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

8 enrolled

Lymphoma, Follicular, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01897571 2024-03-26

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

400 enrolled 22 charts 2 FDA

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02440685 2023-06-07

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

LymphoidMyeloidOther hematologic neoplasm

51 enrolled 18 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Mantle-Cell, Primary Myelofibrosis

NCT04271410 2023-04-18

CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

80 enrolled

Leukemia, Lymphoma, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04648475 2023-04-18

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

40 enrolled

Leukemia, B-Cell, Lymphoma, B-Cell

NCT04649983 2023-04-18

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

40 enrolled

Leukemia, B-Cell, Lymphoma, B-Cell

NCT03994913 2023-04-14

Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma

20 enrolled

Lymphoma, B-Cell

NCT04030195 2023-01-31

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

18 enrolled 13 charts

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT05651100 2022-12-14

Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

50 enrolled

Lymphoma, Lymphoma, B-Cell

NCT01647971 2022-11-21

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

39 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT02361346 2022-08-18

MT-3724NHL001

38 enrolled 20 charts

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

NCT02584920 2022-05-09

A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma

87 enrolled

Lymphoma, B-Cell

NCT01994382 2022-04-05

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

DermatologicLymphoidOther hematologic neoplasm

260 enrolled 33 charts

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT03880279 2022-02-23

TACTIC-19

Phase 1/2 Withdrawn

Phase 1/2 Not yet recruiting

Lymphoma, B-Cell

NCT05091541 2021-10-25

A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

125 enrolled

Lymphoma, B-Cell

NCT04882163 2021-10-05

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Phase 1/2 Withdrawn

Lymphoma, B-Cell

NCT00061425 2021-08-19

Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT00596804 2021-08-18

Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma

39 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00546793 2021-08-16

Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL